natgillin/translations-raw huggingface dataset:
Som følge af en øget plasmastabilitet og intracellulær aktivering via hydrolyse af cathepsin A er tenofoviralafenamid mere effektivt end tenofovirdisoproxilfumarat til indføring af tenofovir i mononukleære celler i perifert blod (PBMC'er, peripheral blood mononuclear cells) (herunder lymfocytter og andre hiv-målceller) og makrofager. 
Due to increased plasma stability and intracellular activation through hydrolysis by cathepsin A, tenofovir alafenamide is more efficient than tenofovir disoproxil fumarate in loading tenofovir into peripheral blood mononuclear cells (PBMCs) (including lymphocytes and other HIV target cells) and macrophages.
I et panel med 67 hiv 1-rekombinante laboratoriestammer med én resistensassocieret mutation på RT-positioner associeret med NNRTI-resistens var de eneste enkeltresistensassocierede mutationer associeret med tab af modtagelighed for rilpivirin K101P og Y181V/I. 
In a panel of 67 HIV-1 recombinant laboratory strains with one resistance-associated mutation at RT positions associated with NNRTI resistance, the only single resistance-associated mutations associated with a loss of susceptibility to rilpivirine were K101P and Y181V/I.
Odefsey bør ikke administreres sammen med andre antiretrovirale lægemidler (se pkt. 
Odefsey should not be co-administered with other antiretroviral medicinal products (see section 4.5).
Der er observeret lavere eksponeringer for rilpivirin (et af indholdsstofferne i Odefsey) under graviditet, hvorfor virusbelastningen bør monitoreres tæt. 
Lower exposures of rilpivirine (one of the components of Odefsey) were observed during pregnancy; therefore viral load should be monitored closely.
Det er ukendt, om rilpivirin eller tenofoviralafenamid udskilles i human mælk. 
It is not known whether rilpivirine or tenofovir alafenamide are excreted in human milk.
2 Denne bivirkning blev ikke observeret i fase 3-studierne med emtricitabin + tenofoviralafenamid i kombination med elvitegravir + cobicistat eller i fase 3-studierne med Odefsey, men den blev identificeret for emtricitabin i kombination med andre antiretrovirale midler i kliniske studier eller efter markedsføring. 
2 This adverse reaction was not observed in the Phase 3 studies of emtricitabine + tenofovir alafenamide in combination with elvitegravir + cobicistat or in the Phase 3 studies with Odefsey but identified from clinical studies or post-marketing experience of emtricitabine when used with other antiretrovirals.
Tenofoviralafenamid er ikke en hæmmer eller induktor af CYP3A in vivo. 
Tenofovir alafenamide is not an inhibitor or inducer of CYP3A in vivo.
b I begge studier blev patienterne stratificeret efter baseline hiv 1-rna (≤ 100.000 kopier/ml, > 100.000 kopier/ml til ≤ 400.000 kopier/ml eller > 400.000 kopier/ml) ved CD4+ celletal (< 50 celler/μl, 50-199 celler/μl eller ≥ 200 celler/μl), og efter region (USA eller uden for USA). 
b In both studies, patients were stratified by baseline HIV-1 RNA (≤ 100,000 copies/mL, > 100,000 copies/mL to ≤ 400,000 copies/mL, or > 400,000 copies/mL), by CD4+ cell count (< 50 cells/µL, 50-199 cells/µL, or ≥ 200 cells/µL), and by region (US or ex US).
• Ciclosporin, et lægemiddel der anvendes til at reducere styrken af kroppens immunsystem: Dette lægemiddel kan øge mængden af rilpivirin og tenofoviralafenamid (indholdsstoffer i Odefsey) i Deres blod. 
• Ciclosporin, a medicine used to reduce the strength of the body's immune system: This medicine can increase the amount of rilpivirine and tenofovir alafenamide (components of Odefsey) in your blood.
Tabel 3: Virologiske resultater af studierne GS-US-292-0104, GS-US-292-0111 ved uge 48 og uge 96 144a og GS-US-292-0109 ved uge 48a 
Table 3: Virologic outcomes of Studies GS-US-292-0104, GS-US-292-0111 at Week 48 and Week 144a, and GS-US-292-0109 at Week 48a
 Hvis noget af dette gælder for Dem, skal De kontakte lægen, før De tager Odefsey. 
 If any of these applies to you, talk to your doctor before taking Odefsey.
Hvis De har glemt at tage Odefsey 
If you forget to take Odefsey
PHOSPHODIESTERASE TYPE 5 (PDE-5)-HÆMMERE Sildenafil (enkelt dosis på 50 mg)/ rilpivirin1 
PHOSPHODIESTERASE TYPE 5 (PDE-5) INHIBITORS Sildenafil (50 mg single dose)/ Rilpivirine1
Det skal De vide, før De begynder at tage Odefsey Tag ikke Odefsey: 
What you need to know before you take Odefsey Do not take Odefsey:
I et klinisk lægemiddelinteraktionsstudie med tenofoviralafenamid, som er mere følsomt over for hæmning af P-gp i tarmene, påvirkede rilpivirin desuden ikke eksponering for tenofoviralafenamid ved samtidig administration, hvilket tyder på, at rilpivirin ikke er en P-gphæmmer in vivo. 
Additionally, in a clinical drug-drug interaction study with tenofovir alafenamide, which is more sensitive to intestinal P-gp inhibition, rilpivirine did not affect tenofovir alafenamide exposures when administered concurrently, indicating that rilpivirine is not a P-gp inhibitor in vivo.
Dosisjustering af Odefsey er ikke nødvendig hos patienter med let nedsat leverfunktion (Child-Pugh klasse A) eller moderat nedsat leverfunktion (Child-Pugh klasse B). 
No dose adjustment of Odefsey is required in patients with mild (Child Pugh Class A) or moderate (Child Pugh Class B) hepatic impairment.
I fase III-studierne (C209 og C215) er lavere eksponering for rilpivirin, som ligner den der ses under graviditet, blevet associeret med øget risiko for virologisk svigt, hvorfor virusbelastningen bør monitoreres tæt (se pkt. 
In the Phase 3 studies (C209 and C215), lower rilpivirine exposure, similar to that seen during pregnancy, has been associated with an increased risk of virological failure, therefore viral load should be monitored closely (see sections 4.6, 5.1 and 5.2).
FTC/TDF + rilpivirinhydrochlorid var non-inferiørt for så vidt angår hiv 1-rna < 50 kopier/ml sammenlignet med FTC/TDF + efavirenz. 
FTC/TDF + rilpivirine hydrochloride was non-inferior in achieving HIV-1 RNA < 50 copies/mL compared to FTC/TDF + efavirenz.
Tenofoviralafenamid er et substrat for organisk aniontransporterende polypeptid (OATP) 1B1 og OATP1B3 in vitro. 
Tenofovir alafenamide is a substrate of organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 in vitro.
ketoconazol fluconazol itraconazol posaconazol voriconazol 
ketoconazole fluconazole itraconazole posaconazole voriconazole
Andel (%) patienter med hiv 1-rna < 50 kopier/ml pr. tidligere behandlingsregimed EFV/FTC/TDF FTC/TDF plus boosted atazanavir E/C/F/TDF 
Proportion (%) of patients with HIV-1 RNA < 50 copies/mL by prior treatment regimend EFV/FTC/TDF FTC/TDF plus boosted atazanavir E/C/F/TDF
Voksne og unge i alderen 12 år og ældre, der vejer mindst 35 kg Én tablet tages én gang daglig sammen med mad (se pkt. 
Adults and adolescents aged 12 years and older, weighing at least 35 kg One tablet to be taken once daily with food (see section 5.2).
• alvorlige hudreaktioner, herunder udslæt, sammen med feber, hævelser og leverproblemer 
• severe skin reactions including rash accompanied by fever, swelling and liver problems
92 % (66/72 patienter) havde HBV DNA < 29 IE/ml ved brug af analyse, hvor manglende data = svigt ved uge 48. 
Ninety-two percent (66/72 patients) had HBV DNA < 29 IU/mL using missing = failure analysis at Week 48.
I forhold til fastende tilstand førte administration af Odefsey sammen med mad hos raske, voksne forsøgspersoner til en øget eksponering for tenofoviralafenamid (AUC) på 45-53 %. 
Relative to fasting conditions, the administration of Odefsey to healthy adult subjects with food resulted in increased tenofovir alafenamide exposure (AUC) by 45-53%.
Tenofovirdiphosphat hæmmer hiv RT, hvilket resulterer i dna-kædeblokering. 
Tenofovir diphosphate inhibits HIV RT, resulting in DNA chain termination.
Emtricitabin fosforyleres af celleenzymer, hvorved der dannes emtricitabintriphosphat. 
Emtricitabine is phosphorylated by cellular enzymes to form emtricitabine triphosphate.
Norgestimat (0,180/0,215/0,250 mg en gang dagligt)/ ethinylestradiol (0,025 mg en gang dagligt)/ emtricitabin/ tenofoviralafenamid (200/25 mg en gang dagligt) 
Norgestimate (0.180/0.215/0.250 mg once daily)/ Ethinylestradiol (0.025 mg once daily)/ Emtricitabine/Tenofovir alafenamide (200/25 mg once daily)
Knogletoksicitet blev observeret som nedsat knoglemineraltæthed hos rotter og hunde ved eksponeringer for tenofovir, der var mindst fire gange større, end hvad der forventes efter administration af Odefsey. 
Bone toxicity was observed as reduced bone mineral density in rats and dogs at tenofovir exposures at least four times greater than those expected after administration of Odefsey.
Hos hiv-inficerede patienter med svær immuninsufficiens ved påbegyndelsen af CART kan der opstå en inflammatorisk reaktion over for asymptomatiske eller residuale opportunistiske patogener, som kan forårsage alvorlige kliniske tilstande eller forværring af symptomer. 
In HIV infected patients with severe immune deficiency at the time of institution of CART, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
mavesmerter1,3, opkastning1,3, forhøjet lipase1, mavegener1, mundtørhed1, flatulens3, diarré3 
abdominal pain1, 3, vomiting1, 3, increased lipase1, abdominal discomfort1, dry mouth1, flatulence3, diarrhoea3
Interaktion er ikke blevet undersøgt med tenofoviralafenamid. 
Interaction not studied with tenofovir alafenamide.
Alvorlige hudreaktioner med systemiske symptomer er blevet rapporteret i forbindelse med erfaring efter markedsføringen for emtricitabin/rilpivirin/tenofovirdisoproxilfumarat, herunder udslæt med feber, blærer, conjunctivitis, angioødem, forhøjede leverfunktionstal og/eller eosinofili. 
Severe skin reactions with systemic symptoms have been reported during post-marketing experience of emtricitabine/rilpivirine/tenofovir disoproxil fumarate including rashes accompanied by fever, blisters, conjunctivitis, angioedema, elevated liver function tests, and/or eosinophilia.
Da rilpivirin i høj grad er bundet til plasmaproteiner, er det usandsynligt, at det i signifikant grad vil fjernes ved hæmodialyse eller peritonealdialyse (se pkt. 
As rilpivirine is highly bound to plasma proteins, it is unlikely that it will be significantly removed by haemodialysis or peritoneal dialysis (see section 4.9).
Odefseys sikkerhed og virkning hos patienter, som samtidig er inficerede med hiv 1 og hepatitis Cvirus (HCV), er ikke klarlagt. 
The safety and efficacy of Odefsey in patients co-infected with HIV-1 and hepatitis C virus (HCV) have not been established.
Croscarmellosenatrium, lactose (som monohydrat), magnesiumstearat, mikrokrystallinsk cellulose, polysorbat 20, povidon. 
Croscarmellose sodium, lactose (as monohydrate), magnesium stearate, microcrystalline cellulose, polysorbate 20, povidone.
Ved samtidig administration af et teststof, den moderate CYP3A-induktor efavirenz, var eksponeringen af tenofoviralafenamid ikke påvirket signifikant. 
Upon co-administration with the moderate CYP3A inducer probe efavirenz, tenofovir alafenamide exposure was not significantly affected.
Rilpivirin er ikke blevet undersøgt hos patienter med svært nedsat leverfunktion (Child-Pugh klasse C) (se pkt. 
Rilpivirine has not been studied in patients with severe hepatic impairment (Child Pugh Class C) (see section 4.2).
Samtidig infektion med hepatitis B- og/eller hepatitis C-virus Emtricitabins, rilpivirins og tenofoviralafenamids farmakokinetik er ikke blevet fuldt evalueret hos patienter med samtidig infektion med hepatitis B- og/eller hepatitis C-virus. 
Hepatitis B and/or hepatitis C virus co-infection The pharmacokinetics of emtricitabine, rilpivirine and tenofovir alafenamide have not been fully evaluated in patients co-infected with hepatitis B and/or C virus.
Seponerede studiemedicin som følge af andre årsager, og sidste tilgængelige hiv 1rna < 50 kopier/mlf 
Discontinued study drug due to other reasons and last available HIV-1 RNA < 50 copies/mLf
36 patienter havde en median alder på 14,5 år, og 55,6 % var piger, 88,9 % var sorte og 11,1 % var asiater. 
Thirty-six patients had a median age of 14.5 years and were 55.6% female, 88.9% Black, and 11.1% Asian.
d Inkluderer patienter, der havde ≥ 50 kopier/ml i uge 48- eller uge 96-vinduet; patienter, der udgik tidligt på grund af manglende eller tab af effekt; patienter, der udgik af andre grunde end manglende eller tab af effekt og på tidspunktet for afbrydelsen havde virustal ≥ 50 kopier/ml. 
d Includes patients who had ≥ 50 copies/mL in the Week 48 or Week 96 window; patients who discontinued early due to lack or loss of efficacy; patients who discontinued for reasons other than lack or loss of efficacy and at the time of discontinuation had a viral value of ≥ 50 copies/mL.
b n = 23 unge (GS-US-292-0106, populationsfarmakokinetisk analyse). 
b n = 23 adolescents (GS-US-292-0106, population PK analysis).
c P-værdi for superioritetstest, der sammenligner procentandelen af virologisk succes, var fra CMH-testen (CochranMantel-Haenszel) stratificeret efter det tidligere behandlingsregime (EFV/FTC/TDF, FTC/TDF plus boosted atazanavir eller E/C/F/TDF). 
c P-value for the superiority test comparing the percentages of virologic success was from the CMH (Cochran-Mantel-Haenszel) test stratified by the prior treatment regimen (EFV/FTC/TDF, FTC/TDF plus boosted atazanavir, or E/C/F/TDF).
I studier hos virologisk supprimerede voksne patienter var der gennem 96 ugers behandling minimale ændringer eller fald i albuminuri(UACR) hos patienter, der fik Odefsey, sammenlignet med stigninger i forhold til baseline hos patienter, der forblev på FTC/RPV/TDF eller EFV/FTC/TDF. 
In studies in virologically suppressed adult patients, through 96 weeks of treatment there were minimal changes or decreases in albuminuria (UACR) in patients receiving Odefsey compared with increases from baseline in patients who stayed on FTC/RPV/TDF or EFV/FTC/TDF.
De hyppigst rapporterede bivirkninger i kliniske studier hos behandlingsnaive patienter, som fik rilpivirinhydrochlorid i kombination med emtricitabin + tenofovirdisoproxilfumarat, var kvalme (9 %), svimmelhed (8 %), unormale drømme (8 %), hovedpine (6 %), diarré (5 %) og søvnløshed (5 %). 
The most frequently reported adverse reactions in clinical studies of treatment-naïve patients taking rilpivirine hydrochloride in combination with emtricitabine + tenofovir disoproxil fumarate were nausea (9%), dizziness (8%), abnormal dreams (8%), headache (6%), diarrhoea (5%) and insomnia (5%).
Seponering af behandlingen med Odefsey hos patienter, som samtidig er inficerede med hiv og HBV, kan være forbundet med svær, akut eksacerbation af hepatitis. 
Discontinuation of Odefsey therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis.
Lægemidler, der inducerer P-gp- og BCRP-aktivitet (f.eks. rifampicin, rifabutin, carbamazepin, phenobarbital) forventes at nedsætte absorptionen af tenofoviralafenamid, hvilket fører til en nedsat plasmakoncentration af tenofoviralafenamid, hvilket kan forårsage en svigtende terapeutisk virkning af Odefsey samt udvikling af resistens. 
Medicinal products that induce P-gp activity (e.g., rifampicin, rifabutin, carbamazepine, phenobarbital) are expected to decrease the absorption of tenofovir alafenamide, resulting in decreased plasma concentration of tenofovir alafenamide, which may lead to loss of therapeutic effect of Odefsey and development of resistance.
Legemsvægten påvirkede ikke rilpivirins farmakokinetik hos pædiatriske patienter i studiet C213 (33 til 93 kg), 
There was no impact of body weight on rilpivirine pharmacokinetics in paediatric patients in Study C213 (33 to 93 kg), similar to what was observed in adults.
4.8), og der skal gives støttende standardbehandling efter behov, herunder observation af patientens kliniske status og monitorering af vitale parametre og EKG (QT-interval). 
If overdose occurs the patient must be monitored for evidence of toxicity (see section 4.8), and standard supportive treatment applied as necessary including observation of the clinical status of the patient and monitoring of vital signs and ECG (QT interval).
Ingen speciel risiko for mennesker blev vist i konventionelle studier af karcinogenicitet og reproduktionsog udviklingstoksicitet. 
No special hazard for humans was revealed in conventional studies of carcinogenic potential and toxicity to reproduction and development.
I kliniske studier hos mennesker resulterede en 10 mg oral dosis af tenofoviralafenamid givet sammen med emtricitabin, cobicistat og elvitegravir, i tenofovirdiphosphatkoncentrationer > 4 gange højere i PBMC'er og > 90 % lavere koncentrationer af tenofovir i plasma sammenlignet med en 245 mg oral dosis af tenofovirdisoproxil (som fumarat) givet sammen med emtricitabin, cobicistat og elvitegravir 
In human clinical studies, a 10 mg oral dose of tenofovir alafenamide given with emtricitabine, cobicistat and elvitegravir resulted in tenofovir diphosphate concentrations > 4-fold higher in PBMCs and > 90% lower concentrations of tenofovir in plasma as compared to a 245 mg oral dose of tenofovir disoproxil (as fumarate) given with emtricitabine, cobicistat and elvitegravir.
I betragtning af alle tilgængelige in vitro-data og data genereret med behandlingsnaive patienter kan følgende resistensassocierede mutationer i hiv 1 RT, hvis de er til stede ved baseline, påvirke aktiviteten af Odefsey: K65R, K70E, K101E, K101P, E138A, E138G, E138K, E138Q, E138R, V179L, Y181C, Y181I, Y181V, M184I, M184V, Y188L, H221Y, F227C, M230I, M230L og kombinationen af L100I og K103N. 
Considering all of the available in vitro data and data generated in treatment-naïve patients, the following resistance-associated mutations in HIV-1 RT, when present at baseline, may affect the activity of Odefsey: K65R, K70E, K101E, K101P, E138A, E138G, E138K, E138Q, E138R, V179L, Y181C, Y181I, Y181V, M184I, M184V, Y188L, H221Y, F227C, M230I, M230L and the combination of L100I and K103N.
Efter flere doser med oral administration af emtricitabin til 20 hiv 1-inficerede forsøgspersoner var (gennemsnitlig ± SD) AUC (areal under kurven) for plasmakoncentration/tid over et doseringsinterval på 24 timer 10,0 ± 3,1 t•µg/ml. 
Following multiple dose oral administration of emtricitabine to 20 HIV-1 infected subjects, the (mean ± SD) area-under the plasma concentration-time curve over a 24-hour dosing interval (AUC) was 10.0 ± 3.1 h•µg/mL.
Tenofovir har aktivitet mod hiv 1, hiv 2 og HBV. 
Tenofovir has activity against HIV-1, HIV-2 and HBV.
Samtidig administration af Odefsey og andre lægemidler, som hæmmer P-gp (f.eks. ketoconazol, fluconazol, itraconazol, posaconazol, voriconazol, ciclosporin), forventes at øge absorptionen og plasmakoncentrationen af tenofoviralafenamid. 
Co-administration of Odefsey with other medicinal products that inhibit P-gp and BCRP activity (e.g., ketoconazole, fluconazole, itraconazole, posaconazole, voriconazole, ciclosporin) is expected to increase the absorption and plasma concentration of tenofovir alafenamide.
I løbet af 144 ugers behandling seponerede ingen forsøgsdeltager E/C/F/TAF på grund af en behandlingsrelateret renal bivirkning, hvorimod 12 forsøgsdeltagere seponerede E/C/F/TDF (p < 0,001). 
Through 144 weeks of treatment, no subject discontinued E/C/F/TAF due to a treatment-emergent renal adverse event compared with 12 subjects who discontinued E/C/F/TDF (p < 0.001).
De hyppigst rapporterede manifestationer er hæmatologiske forstyrrelser (anæmi, neutropeni), metaboliske forstyrrelser (hyperlaktatæmi, hyperlipasæmi). 
The main adverse reactions reported are haematological disorders (anaemia, neutropenia) and metabolic disorders (hyperlactatemia, hyperlipasemia).
Tabel 5: Virologiske resultater fra studierne GS-US-366-1216 og GS-US-366-1160 ved uge 48a og 96b 
Table 5: Virologic outcomes of Studies GS-US-366-1216 and GS-US-366-1160 at Weeks 48a and
I et separat fase 1-studie udelukkende med emtricitabin var gennemsnitlig systemisk eksponering for emtricitabin højere hos patienter med svært nedsat nyrefunktion (estimeret CrCl < 30 ml/min) (33,7 µg•time/ml) end hos forsøgspersoner med normal nyrefunktion (11,8 µg•time/ml). 
In a separate Phase 1 study of emtricitabine alone, mean systemic emtricitabine exposure was higher in patients with severe renal impairment (estimated CrCl < 30 mL/min) (33.7 µg•h/mL) than in subjects with normal renal function (11.8 µg•h/mL).
I forhold til fastende tilstand førte administration af Odefsey sammen med mad hos raske, voksne forsøgspersoner til en øget eksponering for rilpivirin (AUC) på 13-72 %. 
Relative to fasting conditions, the administration of Odefsey to healthy adult subjects with food resulted in increased rilpivirine exposure (AUC) by 13-72%.
Den mediane (Q1, Q3) ændring fra baseline ved uge 144 i total-kolesterol:HDLkolesterol-ratioen var 0,2 (-0,3; 0,7) hos patienter, der fik FTC + TAF, og 0,1 (0,4; 0,6) hos patienter, der fik FTC + TDF (p = 0,006 for forskellen mellem behandlingsgrupperne). 
Median (Q1, Q3) change from baseline at Week 144 in total cholesterol to HDL-cholesterol ratio was 0.2 (-0.3, 0.7) in patients receiving FTC + TAF and 0.1 (-0.4, 0.6) in patients receiving FTC + TDF (p = 0.006 for the difference between treatment groups).
Antacida bør kun administreres enten mindst 2 timer før eller mindst 4 timer efter Odefsey. 
Antacids should only be administered either at least 2 hours before or at least 4 hours after Odefsey.
Odefseys sikkerhed og virkning hos børn, der er yngre end 12 år eller vejer < 35 kg, er endnu ikke klarlagt. 
The safety and efficacy of Odefsey in children younger than 12 years of age, or weighing < 35 kg, have not yet been established.
Tenofoviralafenamid er ikke en hæmmer af CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 eller CYP2D6 in vitro. 
Tenofovir alafenamide is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or CYP2D6 in vitro.
e Inkluderer patienter, der udgik af andre grunde end en bivirkning (AE), død eller manglende eller tab af effekt; f.eks. trak samtykke tilbage, manglende opfølgning, etc. 
e Includes patients who discontinued for reasons other than an adverse event (AE), death, or lack or loss of efficacy; e.g., withdrew consent, loss to follow-up, etc.
Hjælpestoffer, som behandleren skal være opmærksom på Hver tablet indeholder 189,8 mg lactosemonohydrat. 
Each tablet contains 189.8 mg lactose monohydrate.
Baseret på disse begrænsede data lignede sikkerhedsprofilen for emtricitabin + tenofoviralafenamid i kombination med elvitegravir og cobicistat som en fastdosis kombinationstablet hos patienter med samtidig hiv/HBVinfektion den for patienter med hiv 1-monoinfektion. 
Based on these limited data, the safety profile of emtricitabine + tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed-dose combination tablet, in patients with HIV/HBV co-infection, was similar to that in patients with HIV-1 monoinfection.
I studier hos behandlingsnaive voksne patienter var E/C/F/TAF forbundet med en mindre påvirkning af renale parametre (målt efter 144 ugers behandling som eGFRCG og forholdet mellem protein og kreatinin i urinen [UPCR] og efter 96 ugers behandling som forholdet mellem albumin og kreatinin i urinen [UACR]) sammenlignet med E/C/F/TDF. 
In studies in treatment-naïve adult patients, E/C/F/TAF was associated with lower impact on renal safety parameters (as measured after 144 weeks treatment by eGFRCG and urine protein to creatinine ratio [UPCR] and after 96 weeks treatment by urine albumin to creatinine ratio [UACR]) compared to E/C/F/TDF.
Emtricitabintriphosphat hæmmer kompetitivt hiv 1 revers transkriptase (RT), hvilket resulterer i kædeblokering af deoxyribonukleinsyre (dna). 
Emtricitabine triphosphate competitively inhibits HIV-1 reverse transcriptase (RT), resulting in deoxyribonucleic acid (DNA) chain termination.
I løbet af 96 uger med behandling med rilpivirin blev der observeret gennemsnitlige ændringer på 0,1 mg/dl (interval: -0,3 mg/dl til 0,6 mg/dl) for kreatinin og -13,3 ml/min/1,73 m2 (interval:63,7 ml/min/1,73 m2 til 40,1 ml/min/1,73 m2) for eGFR. 
Over 96 weeks of treatment with rilpivirine mean changes of 0.1 mg/dL (range: -0.3 mg/dL to 0.6 mg/dL) for creatinine and -13.3 mL/min/1.73 m2 (range: -63.7 mL/min/1.73 m2 to 40.1 mL/min/1.73 m2) for eGFR were observed.